Replies to post #26381 on Mymetics Corp (MYMX)

[Work Harder]

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

Jan C. Wilschut

https://research.rug.nl/en/publications/first-in-human-phase-i-clinical-trial-of-an-sfv-based-rna-replico

Publication status Published - 3-Feb-2021

Been several months, should look @ Sanders again

Dr. Thomas Staehelin has wore Dr Toon Stegmann out

& Kempers helped

[Work Harder]

Gardasil History

The vaccine was first developed by the University of Queensland in Australia and the final form was made by researchers at the University of Queensland, Georgetown University Medical Center, University of Rochester, and the U.S. National Cancer Institute.[73] Researchers Ian Frazer and Jian Zhou at the University of Queensland have been accorded priority under U.S. patent law for the invention of the HPV vaccine's basis, the VLPs.[74] In 2006, the FDA approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil. According to a Merck press release,[75] by the second quarter of 2007 it had been approved in 80 countries, many under fast-track or expedited review. Early in 2007, GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine, known as Cervarix. In June 2007, this vaccine was licensed in Australia, and it was approved in the European Union in September 2007.[76] Cervarix was approved for use in the U.S. in October 2009.[77]

Harald zur Hausen, a German researcher who suspected, and later helped to prove that genital HPV infection can lead to cervical cancer, was awarded half of the $1.4 million Nobel Prize in Medicine in 2008 for his work. Verification that cervical cancer is caused by an infectious agent led several other groups to develop vaccines against HPV strains that cause most cases of cervical cancer. The other half of the award went to Françoise Barré-Sinoussi and Luc Montagnier, two French virologists, for their part in the discovery of HIV.[78]

Harald zur Hausen was skeptical of the prevailing dogma and postulated that oncogenic human papilloma virus (HPV) caused cervical cancer.[24] He realized that HPV-DNA could exist in an inactive state in the tumours, and should be detectable by specific searches for viral DNA.[78] He and workers at the Pasteur Institute found HPV to be a heterogeneous family of viruses. Only some HPV types cause cancer.[24]

Harald zur Hausen pursued his research for over 10 years searching for different HPV types. [3] This research was difficult because only parts of the viral DNA were integrated into the host genome. He found novel HPV-DNA in cervix cancer biopsies, and thus discovered the new, tumourigenic HPV16 type in 1983. In 1984, he cloned HPV16 and 18 from patients with cervical cancer.[78] The HPV types 16 and 18 were consistently found in about 70% of cervical cancer biopsies throughout the world.[24]

His observation of HPV oncogenic potential in human malignancy provided impetus within the research community to characterize the natural history of HPV infection, and to develop a better understanding of mechanisms of HPV-induced carcinogenesis.[24]

In December 2014, the United States' Food and Drug Administration (FDA) approved a vaccine called Gardasil 9 to protect females between the ages of 9 and 26 and males between the ages of 9 and 15 against nine strains of HPV.[79] Gardasil 9 protects against infection from the strains covered by the first generation of Gardasil (HPV-6, HPV-11, HPV-16, and HPV-18) and protects against five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).[79]

https://en.wikipedia.org/wiki/HPV_vaccine

Under the terms of the share purchase agreement, Antonius Stegmann, co-founder and chief scientific officer (CSO) of Virosome Biologicals, will remain CSO of Virosome Biologicals.

https://www.pharmaceutical-business-review.com/news/2a49fmymetics_to_acquire_virosome_from_norwood_immun-2/

Who handled that Aussie deal

L & S

[Work Harder]

Jean-Paul Prieels joined GlaxoSmithKline Biologicals in 1987 as Associate Director R&D Projects Evaluation. His responsibilities gradually expanded to lead the global vaccine R&D development activities in Rixensart, Belgium.

Pevion has in-house development capability and expertise, including a state-of-the-art and industrially scalable GMP manufacturing process. Located near Bern, Pevion was established by its founding fathers, Bachem AG (SWX: BANB) and Berna Biotech (now Crucell, a Johnson & Johnson subsidiary). To date, Pevion has raised a total of CHF 45 million to date from its founders and investors, BZ Bank, CCP and BB Biotech Ventures.

https://www.asx.com.au/asxpdf/20090309/pdf/31gh5dqy4v7c74.pdf

https://www.sec.gov/Archives/edgar/data/927761/000095015209002330/l35768aexv99w1.htm